Navigation Links
Selexis Announces Expansion of R&D License Agreement with Amgen
Date:2/20/2013

GENEVA, Feb. 20, 2013 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development.  Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D. 

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable," said Igor Fisch , Ph.D., President and CEO of Selexis. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.  This current agreement is built on the long-standing relationship between our two companies since 2004." 

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information, visit http://www.selexis.com

Media Inquires
Robert Meister
Selexis SA
Tel: +1 (602) 953-1716
Email: robert.meister@selexis.com

 


'/>"/>
SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
2. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
3. Incisive Surgical Announces Sale Of One-Millionth INSORB Stapler
4. BioMed Realty Trust Announces Exercise Of Option To Purchase Additional Shares Of Common Stock
5. UBM Canon, the Global Authority on the MedTech Industry, Announces Senior Editor for MD+DI (Medical Device & Diagnostic Industry)
6. Silver Lining Textiles, Manufacturers of Anti-microbial Under Scrub Garments for the Healthcare Industry, Announces Their Availability Through Amazon.com
7. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
8. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
9. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
10. Vomaris Announces initiation of study with Walter Reed National Military Medical Centers Combat Wound Initiative
11. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... Feb. 19, 2017   AC Group Inc. , ... ranking of vendors in the PMS/EHR healthcare marketplace, will ... system requirements to succeed in this ecosystem at HIMSS,17. ... together information obtained from over 200 ACOs, compared and ... and services companies that are providing different pieces of ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
(Date:2/18/2017)... , Feb. 17, 2017  Pharmaceutical companies have long ... products either in development or already on the market.   ... the pharma industry to alter how it manages advisory board ... leader Best Practices, LLC conducted a new study focused on ... ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... 20, 2017 , ... Researchers at the University of Pittsburgh School of Medicine ... that may predict response to a particular class of drugs, not just in patients ... The new findings were published in Proceedings of the National Academy of Science. , ...
(Date:2/20/2017)... ... 2017 , ... The StayWell Company and VUCA Health ... health risks, foster behavior change and improve health literacy among patients. VUCA Health, which ... demonstration of its video capability at StayWell booth 3443 during HiMSS. , The ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies Inc., the world ... visit this week at HIMSS 2017 Conference & Exhibition. The event brings more ... will be featured in the conference’s Connected Health Experience section, an area specifically ...
(Date:2/20/2017)... ... ... a Population Health Software Company, is pleased to announce a move to a larger office ... the size of the previous location while bringing life back to a medical practice building ... are excited to expand our footprint to better serve our growing client base. We ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's Hospital ... A topping out ceremony on Friday marked the halfway point of construction and lifting ... in Fall 2018, will serve as a center for innovation aimed at finding new ...
Breaking Medicine News(10 mins):